• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Wall Street Beat

Intersect ENT reels in losses, beats revenue estimates for Q4

March 1, 2017 By Sarah Faulkner

Intersect ENT

Shares in Intersect ENT (NSDQ:XENT) fell slightly today even though the drug-device company met expectations on Wall Street with its 4th quarter results. The Menlo Park, Calif.-based company pared losses to -$4.8 million, or -17¢ per share, on sales of $24.2 million for the 3 months ended Dec. 31, for bottom-line growth of 15.8% on sales growth […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Otolaryngology Ear, Nose & Throat, Wall Street Beat Tagged With: Intersect ENT Inc.

DexCom beats Street with Q4 earnings

March 1, 2017 By Sarah Faulkner

Dexcom

Shares in DexCom Inc. (NSDQ:DXCM) rose today after the medical device maker met expectations on Wall Street with its 4th quarter results. The San Diego-based company posted a loss of -$7.4 million, or -9¢ per share, on sales of $171.2 million for the 3 months ended Dec. 31, for bottom-line loss of -593.3% on sales growth […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: DexCom Inc.

BioCardia, Johns Hopkins treats first patient with CardiAmp cell therapy in Phase III trial

February 28, 2017 By Sarah Faulkner

BioCardia

Johns Hopkins, the Maryland Stem Cell Research Fund and BioCardia (NSDQ:BCDA) said today that the 1st patient has been treated in a pivotal Phase III trial of the CardiAmp cell-based therapy for the treatment of ischemic heart failure. The investigational therapy was designed to deliver a dose of a patient’s own bone marrow cells directly […]

Filed Under: Cardiovascular, Clinical Trials, Featured, Regenerative Medicine, Wall Street Beat Tagged With: BioCardia, Johns Hopkins

FDA asks Titan for more info before clinical trial of ropinirole implant

February 28, 2017 By Sarah Faulkner

Titan Pharmaceuticals

Titan Pharmaceuticals (NSDQ:TTNP) said today that the FDA put a hold on the clinical trial of its ropinirole implant and told the company to submit more information to the federal watchdog. After it completed an initial review of the implant’s Investigational New Drug application, the FDA asked Titan for final release test data on its ropinirole […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Neurological, Wall Street Beat Tagged With: Titan Pharmaceuticals

Insulet slides on Q4 earnings miss

February 28, 2017 By Brad Perriello

Insulet

Insulet (NSDQ:PODD) shares are under pressure this morning after the diabetes company missed expectations for its 4th-quarter earnings, despite beating Wall Street’s consensus sales forecast. Billerica, Mass.-based Insulet narrowed its losses by -66.6%, to -$9.1 million, or -16¢ per share, on sales growth of 23.6% to $103.6 million for the 3 months ended Dec. 31, compared […]

Filed Under: Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Insulet

TearLab readies for reverse split

February 28, 2017 By Sarah Faulkner

TearLab

Shares in TearLab Corp. (NSDQ:TEAR) said last week that its board approved a 1-for-1o reverse split of its common stock. The company’s shares have fallen nearly 20% since the beginning of the month. The San Diego, Calif.-based company’s move reduced the total number of authorized shares of its common stock from 95 million t0 9.5 […]

Filed Under: Diagnostics, Featured, Optical/Ophthalmic, Wall Street Beat Tagged With: TearLab

Elixir Medical’s DeSyne stent tops Medtronic’s Endeavor after 5 years

February 28, 2017 By Sarah Faulkner

Elixir Medical‘s novolimus-eluting stent, DeSyne, outperformed Medtronic‘s (NYSE:MDT) zotarolimus-eluting stent, Endeavor, according to long-term data from Elixir’s Excella II trial. The study enrolled 210 patients with 2 or more de novo lesions in 2 different epicardial vessels. Researchers randomly assigned patients in a 2:1 ratio to the novolimus-eluting stent or the zotarolimus-eluting stent. The device emits a low […]

Filed Under: Clinical Trials, Featured, Vascular, Wall Street Beat Tagged With: Elixir Medical Corporation, Medtronic

Clearside bails on AMD, all-in on diabetic macular edema

February 27, 2017 By Sarah Faulkner

Clearside Biomedical

Clearside Biomedical (NSDQ:CLSD) said today it will redirect its R&D efforts from its pre-clinical axitinib wet age-related macular degeneration therapy to its Zuprata diabetic macular edema treatment. The Alpharetta, Ga.-based company said that recent trial results from other companies investigating combination therapies for wet AMD have led Clearside to reconsider its proprietary suspension formulation of […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Research & Development, Wall Street Beat Tagged With: Clearside Biomedical

Report finds pharma companies limited January list price hikes

February 27, 2017 By Sarah Faulkner

Pills

Drug-makers didn’t raise list prices for as many drugs in January compared to last year and they initiated fewer hikes of 10% or more, according to analysis by Raymond James & Associates. Although 5.5% of price increases reached the 10% level in January this year, 15% did last year and 20% did 2 years ago. […]

Filed Under: Featured, Pharmaceuticals, Wall Street Beat Tagged With: AbbVie, Allergan, johnsonandjohnson, Marathon Pharmaceuticals, Merck, Mylan, Novo Nordisk

OncoSec wins fast track designation for electroporation combo therapy

February 27, 2017 By Sarah Faulkner

OncoSec Medical

OncoSec Medical (NSDQ:ONCS) said today that it won Fast Track Designation from the FDA for its ImmunoPulse IL-12 electroporation gene therapy for the treatment of metastatic melanoma. The biotech company’s electroporation device is designed to locally deliver DNA-based interleukin-12 to stimulate the immune system and fight off cancer cells. The ImmunoPulse device delivers a sequence […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Oncology, Regulatory/Compliance, Wall Street Beat Tagged With: OncoSec Medical

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 173
  • Page 174
  • Page 175
  • Page 176
  • Page 177
  • Interim pages omitted …
  • Page 193
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS